Metabolic complications such as dyslipidemia, insulin resistance, and altered fat distribution
(loss of subcutaneous fat and relatively increased central fat) are common in adults infected
with the human immunodeficiency virus who are receiving highly active antiretroviral therapy
and may increase their risk of cardiovascular disease. This review discusses progress in
understanding the pathogenetic mechanisms and treatment strategies for addressing
cardiovascular risk in this population.